Apr 11 |
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
|
Apr 8 |
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
|
Mar 28 |
Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO
|
Mar 28 |
Boundless Bio prices $100M IPO at $16 per share
|
Mar 27 |
Boundless Bio Announces Pricing of Initial Public Offering
|